At Pliant Therapeutics, we recognize that our success depends on the excellence of our people. With this in mind, we are highly vested in the recruitment, training and development of our employees.
We are looking for exceptional candidates who are dedicated to our corporate values and are interested in being a part of a team that is committed to developing a pipeline of innovative therapeutics to treat major unmet medical needs.
By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery.
Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.

Show more
HQRedwood City, US
Size (employees)42 (est)+8%
Pliant Therapeutics was founded in 2016 and is headquartered in Redwood City, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Pliant Therapeutics

Bernard Coulie

Bernard Coulie

President and Chief Executive Officer
Katerina Leftheris

Katerina Leftheris

Vice President of Chemistry
Hans Hull

Hans Hull

Chief Business Officer
David Morgans

David Morgans

Vice President of Drug Discovery and Early Development
Patrick Andre

Patrick Andre

Vice President of Biology
Scott Turner

Scott Turner

Vice President Translational Sciences
Show more

Pliant Therapeutics Office Locations

Pliant Therapeutics has an office in Redwood City
Redwood City, US (HQ)
150 700 Saginaw Dr
Show all (1)
Report incorrect company information

Pliant Therapeutics Financials and Metrics

Summary Metrics

Founding Date


Pliant Therapeutics total Funding

$107 m

Pliant Therapeutics latest funding size

$62 m

Time since last funding

3 months ago

Pliant Therapeutics investors

Pliant Therapeutics's latest funding round in July 2018 was reported to be $62 m. In total, Pliant Therapeutics has raised $107 m
Show all financial metrics
Report incorrect company information

Pliant Therapeutics Blogs

Pliant Therapeutics Announces Research Collaboration with Cleveland Clinic to Develop New Disease Targets for Gastrointestinal Fibrosis

SOUTH SAN FRANCISCO, CA — September 6, 2018 — Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that they have entered into a multi-year joint research collaboration with Cleveland Clinic to acc…

Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis

SOUTH SAN FRANCISCO, CA — August 6, 2018 — Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company’…

Pliant Therapeutics Raises $62 Million in Series B Financing to Advance Therapies for Fibrotic Diseases

SOUTH SAN FRANCISCO, CA — July 16, 2018 — Pliant Therapeutics, Inc. today announced that it has raised $62 million in a Series B financing. The funds will support the initiation and proof-of-concept clinical trials in idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), as w…

Pliant Therapeutics Company Life and Culture

Report incorrect company information